It's the "exercise in a vial" peptide longevity and metabolic circles keep talking about — and the claims run far ahead of the human evidence. Here's what MOTS-c actually is, what the science does and doesn't show, and exactly where it stands with the FDA in 2026.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide — one of the first peptides discovered to be encoded by mitochondrial DNA (within the 12S rRNA gene) rather than by nuclear DNA. The name stands for "mitochondrial open reading frame of the 12S rRNA-c." In research it has been investigated mostly for metabolism: it activates the AMPK pathway, influences glucose uptake in skeletal muscle, and has been described as an "exercise mimetic" because circulating levels rise with physical activity. It is not a vitamin, a supplement, or an approved medication.
The honest headline: most of the evidence is preclinical — cell and animal models, with human work still early. Studies in mice report effects on diet-induced obesity and insulin resistance, but claims that it delivers those benefits in people, or replaces exercise, run ahead of the data. That gap between loud marketing and thin human evidence is exactly what this page exists to close.
MOTS-c is not an FDA-approved drug. Its status has moved a lot recently, and the nuance matters:
Want the live picture? Our regulatory-status tracker shows exactly where MOTS-c and other peptides stand right now, with the dated primary sources.
In cell and animal models, MOTS-c has been reported to activate AMPK signaling, enhance glucose uptake into skeletal muscle, and modulate the folate-methionine cycle, with mouse studies describing protection against diet-induced obesity and insulin resistance. Plasma and muscle levels appear to decline with age, and treatment has been reported to restore insulin sensitivity in older mice — part of why it's framed as an exercise mimetic.
In humans, the picture is far thinner: circulating MOTS-c has been observed to rise with exercise, but controlled clinical trials of administered MOTS-c are early and limited, and much of what circulates online is anecdote, not data. That doesn't mean it "doesn't work" — it means the evidence needed to say it does, safely, in people, largely isn't there yet. Treat confident metabolic and anti-aging claims with skepticism.
Because MOTS-c isn't FDA-approved, there is no official dosing. Commonly reported subcutaneous doses sit around 5–10 mg per week. These are not approved or standardized doses — they reflect what clinics and the wider community commonly report using today, shared for education, not medical advice.
MOTS-c typically ships as a freeze-dried (lyophilized) powder that must be reconstituted with bacteriostatic water before it's a liquid. The math — concentration and the volume to draw — trips a lot of people up, and a misplaced decimal is an easy way to dose 10× off. That's what our free tool is for:
Human safety data is limited. Reported effects in the literature are generally mild, but long-term safety in humans is simply not well established, and product quality varies enormously between sources. Because much of the supply is research-use-only and unregulated, purity, sterility, and accurate labeling are real concerns — which is why sourcing and testing matter as much as the molecule itself.
If you're considering MOTS-c, the responsible path runs through a licensed provider who can weigh your situation, not a checkout page. Questions worth asking: Is there third-party testing and a certificate of analysis? What's the source and is it disclosed? What does the provider make of the current legal status? This isn't legal or medical advice — it's the baseline diligence any unapproved substance deserves.
It's been called an exercise mimetic because circulating levels rise with activity and it activates AMPK in studies. But those effects are mostly from cell and animal models — it is not a proven substitute for exercise in people.
No. MOTS-c is a mitochondrial-derived peptide studied for metabolism; it is not an approved GLP-1 medication and works through different pathways. We cover GLP-1 peptides separately in the library.
No. It is not FDA-approved. It was removed from Category 2 in April 2026 but is not on the 503A bulks list. It's been selected for the July 2026 PCAC meeting and remains unlisted and under review until then.
We don't sell peptides and we don't direct consumers to buy unapproved substances. If a licensed provider determines it's appropriate, sourcing and testing should be part of that conversation.
Educational information only. Not medical, legal, or regulatory advice, not a dosing, treatment, or efficacy claim, and not a recommendation to obtain or use any substance. Many peptides are not FDA-approved; some are labeled research-use-only ("not for human use"). Regulatory status changes frequently — verify independently and consult a licensed provider before any health decision. Published by Health Pro Distributors. © 2026.